George Medicines, a late-stage drug development company transforming the management of cardiometabolic disease, today announced that all patients have been enrolled in its Phase III active-controlled trial evaluating the efficacy and safety of GMRx2, the Company’s lead pipeline candidate, as a treatment for hypertension including first-line therapy.
July 12, 2023
· 4 min read